Metabolic Endotoxemia Initiates Obesity and Insulin Resistance

(Downloading may take up to 30 seconds. If the slide opens in your browser, select File -> Save As to save it.)

Click on image to view larger version.

FIG. 5.
FIG. 5.

The CD14 null mutation prevents the effect of LPS-induced obesity and diabetes. A: Body weight gain (g) in WT mice infused with saline (WT-CT; n = 13) or LPS (WT-LPS; n = 14) and CD14 mutant mice infused with saline (CD14-CT; n = 13) or LPS (CD14-LPS; n = 12) for 4 weeks using subcutaneous osmotic pumps. B: Visceral and subcutaneous adipose tissue weight (percentage of body weight) in WT-CT (n = 13) (□), WT-LPS (n = 14) (▪), CD14-CT (n = 13) (▒), and CD14-LPS (n = 12) (Graphic) mice. C: Plasma glucose concentration (mmol/l) following an intraperitoneal glucose load (1 g/kg) in WT-CT (n = 6) (▪), WT-LPS (n = 6) (▴), CD14-CT (n = 5) (□), and CD14-LPS (n = 6) (•) mice. The inset represents the area under curve of the same groups. D: Plasma insulin (pmol/l) concentration 30 min before (−30) and 30 min after (30) intraperitoneal glucose administration in WT-CT (n = 6) (□), WT-LPS (n = 6) (▪), CD14-CT (n = 5) (Graphic), and CD14-LPS (n = 6) (▒) mice. E: Liver weight (percentage of body weight) in WT-CT (n = 13), WT-LPS (n = 13), CD14-CT (n = 12), and CD14-LPS (n = 13) mice. F: Liver triglycerides (μmol/liver) in WT-CT (n = 12), WT-LPS (n = 9), CD14-CT (n = 5), and CD14-LPS (n = 6) mice. Data are means ± SE. Data with different superscript letters are significantly different at P < 0.05, according to the post hoc ANOVA statistical analysis.

This Article

  1. Diabetes vol. 56 no. 7 1761-1772